Rani Therapeutics Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
28.4%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.18next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 2026 Earnings Release | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Contract Revenue Annually1.6M
Cash, Cash Equivalents and Marketable Securities Quarterly43.4M
Net Loss Annually41M
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Regain compliance by lifting bid price to at least $1.00 for 10 consecutive business days, or evaluate a reverse stock split / transfer to Nasdaq Capital Market.
- RT-114 Phase 1 Clinical Trial ProgressTrigger: Completion of Phase 1 safety, tolerability, and pharmacokinetic evaluationAction: Review topline pharmacokinetic and safety data to determine advancement to Phase 2 clinical trials.
- RT-102 Phase 2 Osteoporosis Trial ReadoutTrigger: Topline Phase 2 results expected in the second half of 2026Action: Analyze efficacy and safety data to support pivotal development and potential licensing discussions.
Research as of 20 Jun 2026